solid
tumor
tumor
interior
display
high
cellular
densiti
multipl
cell
type
malign
normal
stromal
cell
interdigit
strand
extracellular
matrix
ecm
poorli
defin
tissu
stromal
cell
typic
consist
fibroblast
macrophag
neutrophil
immun
cell
type
tumorassoci
fibroblast
sourc
bulk
acellular
tissu
tumor
larg
made
polysugar
glycoprotein
collagen
laminin
fibronectin
proteoglycan
hyaluronan
water
form
dens
matrix
around
cancer
cell
matrix
provid
structur
support
also
haptotact
chemotact
guidanc
cancer
cell
moreov
prevail
tumor
interstitium
rich
solubl
angiogen
factor
member
vascular
endotheli
growth
factor
vegf
famili
cellular
growth
factor
includ
endotheli
growth
factor
egf
basic
fibroblast
growth
factor
fgf
plateletderiv
growth
factor
pdgf
pleiotroph
factor
particularli
transform
growth
factor
tgf
beta
addit
tumor
stromal
cell
secret
cytokin
chemokin
interleukin
il
il
tumor
necrosi
factor
tnf
alpha
stromal
cellderiv
factor
sdf
macrophag
migrat
inhibitori
factor
mif
one
hand
recruit
stromal
progenitor
cell
tumor
hand
curb
activ
antigenpres
cell
antitumor
cell
sever
independ
cancer
type
high
serum
level
il
il
indic
poor
prognosi
aberr
tumor
stromal
growth
combin
overproduct
matrix
lead
high
interstiti
pressur
tumor
prevent
later
diffus
therapeut
compound
within
tumor
tight
cellular
compact
combin
high
tumor
prolifer
rate
also
caus
physic
crowd
put
constraint
oxygen
due
aberr
angiogenesi
ruptur
haphazard
vessel
mostli
incomplet
result
chronic
tissu
hypoxia
toward
tumor
core
cancer
cell
exist
crowdinghypox
cytokinegrowth
factorperpetu
chronic
state
stress
upregul
number
key
cellular
molecul
function
collect
defens
wide
rang
therapi
includ
oncolyt
virus
properti
oncolyt
virus
statu
clinic
develop
well
variou
deliveri
option
review
elsewher
review
provid
overview
two
main
intratumor
barrier
oncolyt
viru
spread
extracellular
tumor
makeup
intracellular
antivir
defens
mechan
tumor
cellular
structur
composit
may
concert
abund
extracellular
matrix
ecm
deposit
pose
sever
hurdl
system
viru
entri
propag
infect
within
tumor
extracellular
matrix
complex
dens
network
consist
multipl
protein
glycoprotein
polysaccharid
includ
collagen
laminin
fibronectin
proteoglycan
hyaluron
acid
interstiti
fluid
pressur
ifp
tumor
surround
blood
lymphat
vessel
mainli
creat
high
cell
densiti
form
increas
physic
pressur
outward
allow
free
diffus
therapeut
high
ifp
gener
predict
aggress
tumor
phenotyp
tumor
cell
tend
escap
tumor
margin
pressur
drop
thu
facilit
spread
metastat
cell
hand
therapeut
viru
interstiti
fluid
concentr
gradient
may
pose
hurdl
passiv
diffus
viabl
region
typic
rim
may
occur
mainli
outward
given
limit
arsen
known
chemic
allevi
tumor
compact
poor
penetr
drug
gener
tumor
tissu
consider
problem
may
easi
tackl
strategi
discuss
virus
passiv
particl
reli
either
radial
celltocel
spread
solubl
diffus
across
concentr
gradient
reach
target
cell
propag
infect
tumor
matrix
critic
regard
block
form
spread
passiv
diffus
virus
may
physic
fit
strand
ecm
shown
oncolyt
herp
viru
outer
diamet
nm
whose
spread
could
improv
matrixdegrad
bacteri
collagenas
coinject
bilbao
cowork
show
adenoviru
entri
experiment
hepatocellular
carcinoma
nodul
liver
immunocompet
rat
follow
intraven
intraport
inject
directli
relat
thick
ecm
capsul
envelop
nodul
hand
found
use
semliki
forest
viru
outer
diamet
nm
even
upon
intratumor
inject
spread
block
ecm
form
physic
barrier
viru
infect
figur
foremost
option
reduc
interstiti
fluid
pressur
remov
physic
molecul
barrier
impos
ecm
use
matrixdegrad
enzym
act
digest
collagen
fibrin
type
fibrillar
matrix
deposit
creat
space
cell
cluster
glycosaminoglycan
polym
known
limit
fluid
movement
tumor
simultan
strategi
may
also
expos
cell
surfac
virus
increas
likelihood
infect
studi
kuriyama
trypsin
collagenasedispas
inject
subcutan
glioma
xenograft
immunocompromis
mice
follow
report
adenoviru
type
ecmdegrad
enzym
increas
tumor
transduct
viru
dose
got
high
transduct
efficaci
suffer
demonstr
balanc
ecmdegrad
oncolyt
viru
efficaci
anoth
studi
treatment
tumor
vaccinia
viru
produc
matrix
metalloproteas
mmp
result
reduct
collagen
iv
fibril
increas
viru
penetr
tumor
yield
elev
viru
titer
hong
et
al
target
orthotop
neuroblastoma
xenograft
engin
express
oncolyt
hsv
achiev
increas
viru
distribut
compar
control
tumor
similar
result
obtain
human
soft
tissu
sarcoma
overexpress
inject
oncolyt
hsv
tumor
contain
significantli
less
sulfat
glycosaminoglycan
compar
control
tumor
enzym
protein
effector
either
engin
viru
express
cassett
provid
exogen
includ
hyaluronidas
decorin
variou
mmp
notabl
peptid
hormon
normal
express
particular
phase
pregnanc
possess
tissuedegrad
activ
instead
induc
number
key
collagendegrad
proteas
seemingli
tumorspecif
manner
beyer
show
relaxin
express
murin
stem
cell
improv
trastuzumab
penetr
therapi
outcom
syngen
tumor
model
anoth
studi
chimer
adenoviru
express
relaxin
show
increas
tumor
transduct
viru
dissemin
sever
strategi
increas
penetr
therapeut
tumor
develop
stromalecm
capsul
tumor
nodul
act
physic
barrier
viru
entri
follow
intraven
inject
possibl
improv
tumor
infect
administ
vasoact
compound
angiotensin
ii
histamin
nitroglycerin
viru
interest
vasculatur
per
se
would
expect
alter
influenc
physic
composit
ecm
collagen
strand
thick
instead
viru
access
tumor
improv
like
increas
access
blood
via
tumorstromaladjoin
vessel
interestingli
studi
oncolyt
herp
viru
antivegf
monoclon
antibodi
bevacizumab
given
intraven
viru
inject
gave
poorer
antitumor
efficaci
given
viru
studi
show
hsv
abl
enter
infect
tumor
better
leaki
vasculatur
compar
bevacizumabnorm
vasculatur
vascular
normal
bevacizumab
still
gave
superior
combin
efficaci
viru
alreadi
tumor
effect
like
depend
alter
physic
biolog
properti
tumor
includ
interstiti
pressur
oxygen
anoth
studi
antivegfa
antibodi
inject
nude
mice
harbor
human
glioma
xenograft
led
increas
express
reduct
collagen
fiber
content
facilit
improv
distribut
oncolyt
adenoviru
within
tumor
tissu
gener
target
tumor
vasculatur
oncolyt
virus
includ
agent
affect
tumor
vasculatur
combin
regimen
gain
interest
interest
see
specif
studi
vascularact
agent
may
affect
physic
barrier
oncolyt
virus
virus
need
extracellular
step
propag
infect
member
herp
poxviru
famili
may
abl
spread
celltocel
exampl
abl
infect
neighbor
cell
via
later
tight
junction
manner
depend
glycoprotein
e
vaccinia
viru
hand
induc
call
actintail
actinfilamentdriven
membran
protrus
plasma
membran
harbor
singl
viru
particl
outer
tip
actin
tail
activ
deliv
deposit
viru
particl
onto
even
neighbor
cell
later
spread
without
extracellular
step
may
circumv
neutral
immun
well
physic
obstacl
tumor
microenviron
impos
abil
engin
virus
normal
possess
promis
strategi
engin
ov
express
membranefusogen
gene
mfg
gibbon
ape
leukemia
viru
galv
glycoprotein
reptilian
reoviru
protein
fast
membran
glycoprotein
h
f
measl
viru
quit
intriguingli
express
sever
differ
mfg
oncolyt
adenoviru
synerg
chemotherapi
antitumor
efficaci
vitro
vivo
suggest
membran
fusion
facilit
later
spread
also
chemotherapeut
otherwis
would
occur
compact
tumor
potenti
limit
celltocelldepend
spread
howev
may
membranefre
physic
barrier
ecm
may
still
pose
barrier
spread
also
unclear
whether
mfg
mechan
later
spread
may
assist
reach
distant
tumor
nest
strategi
allevi
matriximpos
restrict
oncolyt
virus
discuss
elsewher
tumor
epitheli
origin
mostli
retain
firm
cellular
integr
seen
origin
adhes
intercellular
configur
sever
virus
use
cellular
receptor
locat
paracellular
tight
junction
may
problemat
tightli
pack
tumor
adenoviru
c
group
virus
use
coxsackieadenoviru
receptor
car
primari
entri
point
wherea
adenoviru
group
member
measl
viru
edmonston
use
complement
bind
molecul
cellular
receptor
adenoviru
group
serotyp
entri
occur
use
car
preferenti
locat
within
tight
junction
hidden
viru
bind
also
complement
receptor
ascrib
role
mainten
epitheli
cell
integr
interact
ecadherincatenin
network
observ
impli
reach
potenti
entri
site
tumor
cell
viru
must
find
way
junction
space
moreov
becom
increasingli
clear
exampl
glioma
tumor
tradit
target
serotyp
adenovirus
often
express
low
level
car
instead
much
higher
level
beyond
tight
junction
hide
multipl
viru
receptor
contain
network
adhes
molecul
includ
cadherin
claudin
occludin
perturb
associ
aggress
diseas
mani
type
cancer
sinc
tight
junction
also
contain
import
receptor
mediat
tumorpromot
signal
target
monoclon
antibodi
notabl
would
highli
use
develop
strategi
temporarili
loosen
tight
junction
cost
transient
increas
tumor
metastat
risk
one
interest
approach
exploit
natur
propens
adenoviru
serotyp
part
natur
life
cycl
creat
dodecahedr
particl
ptdd
consist
viral
capsid
protein
penton
base
fiber
open
tight
junction
bind
dissolv
dimer
reduc
ecadherin
express
develop
specif
tightjunct
open
molecul
adenoviru
type
use
ptdd
promot
infect
open
tight
junction
ahead
infect
maxim
access
analog
administ
human
tumor
xenograft
facilit
penetr
trastuzumab
much
deeper
tumor
tissu
monoclon
antibodi
administ
moreov
synerg
sever
chemotherapeut
solid
tumor
model
back
find
oncolyt
sfv
show
extracellular
matrix
tumor
cell
compact
restrict
viru
spread
oncolyt
efficaci
believ
combin
approach
target
tight
junction
extracellular
matrix
prove
effect
futur
virotherapi
develop
figur
altern
approach
increas
tumor
penetr
oncolyt
virus
alter
tumor
cell
morpholog
statu
notabl
cell
death
particular
type
cell
death
induc
viru
shown
affect
viru
distribut
within
tumor
mass
studi
nagano
et
al
administr
apoptosisinduc
paclitaxel
inject
oncolyt
herp
simplex
viru
increas
viru
dissemin
tumor
allow
diffus
tunnel
creat
shrinkingdi
tumor
cell
mainten
physiolog
adher
essenti
proper
ecm
function
retain
cellular
integr
therefor
potenti
caveat
use
ecm
degrad
proteolyt
enzym
tightjunct
open
risk
neoplast
cell
detach
tumor
ecm
increas
risk
metastasi
ecmdegrad
tight
junction
open
may
oper
innocu
also
chanc
loss
ecadherin
via
proteas
via
nonspecif
deregul
tight
junction
integr
ecmmodul
therapi
could
trigger
protumorigen
signal
possibl
drive
epithelialtomesenchym
transit
one
studi
show
ectop
relaxin
express
stimul
mmp
express
enhanc
breast
cancer
invas
wherea
anoth
paper
found
short
term
relaxin
exposur
increas
breast
cancer
cell
motil
wherea
long
term
express
reduc
motil
cancer
invas
context
oncolyt
virus
lavillaalonso
test
sever
proteas
includ
hyaluronidas
relaxin
macrophag
metalloelastas
show
could
assist
adenoviru
entri
tumor
yet
author
detect
treatmentinduc
metastas
increas
tumor
invas
anoth
strategi
possibl
balanc
put
risk
tightjunct
disrupt
could
use
wntdepend
oncolyt
virus
tumor
invari
fenestr
host
fibroblast
myeloid
cell
nontransform
cell
driven
cancerinduc
cue
adopt
variou
reprogram
phenotyp
promot
tumor
angiogenesi
growth
alter
tumor
respons
therapi
normal
play
role
immun
homeostasi
pathogen
sens
also
respond
influenc
oncolyt
viru
infect
tumor
fulci
et
al
report
inject
oncolyt
directli
glioblastoma
tumor
parenchyma
trigger
upregul
monocyt
marker
rapid
clearanc
viru
like
execut
infiltr
phagocyt
cell
clodron
liposom
use
deplet
macrophag
vivo
author
observ
increas
viru
titer
brain
tumor
concomit
reduct
peripher
macrophag
anim
spleen
suggest
cell
migrat
tumor
upon
viru
inject
limit
overal
oncolyt
efficaci
cell
reduc
peripher
macrophag
deplet
argu
cell
recruit
tumor
treatment
could
elimin
live
glioma
slice
ex
vivo
result
increas
viru
replic
macrophag
may
secret
antivir
type
interferon
constitut
low
subnanomolar
level
recent
liu
et
al
show
tumorresid
macrophag
induc
protect
antivir
state
ovarian
breast
tumor
led
resist
oncolyt
vesicular
stomat
viru
vsv
infect
type
ifn
signal
inhibitor
ruxolitinib
revers
resist
facilit
vsv
replic
macrophageprotect
cancer
cell
tempt
specul
tumorresid
macrophag
also
render
syngen
dbt
mous
glioma
complet
refractori
oncolyt
alphaviru
cell
quit
infect
vitro
live
glioma
slice
regain
sensit
viru
within
h
indic
dilut
ifni
macrophag
close
relat
myeloid
suppressor
cell
predomin
stromal
cell
type
mani
tumor
activ
recruit
cancer
progress
heavi
macrophag
presenc
tumor
indic
tumor
may
resist
oncolyt
virotherapi
unless
deplet
precondit
would
use
moreov
part
earli
immun
respons
viru
infect
monocyt
cell
rapidli
recruit
tumor
follow
intratumor
viru
inject
one
studi
deplet
either
cell
vegf
secret
cell
mice
treat
oncolyt
greatli
increas
oncolyt
efficaci
tent
link
protumorigen
antivir
angiogen
mechan
anoth
key
protumorigen
signal
employ
mani
tumor
upregul
receptor
chemokin
also
known
recruit
stromal
cell
express
maintain
tumor
recruit
addit
cell
support
tumor
expans
invas
endotheli
cell
progenitor
contribut
neovascular
inde
high
express
neg
prognost
factor
mani
cancer
oncolyt
vaccinia
viru
engin
express
solubl
antagonist
show
improv
intratumor
viru
replic
increas
vascular
disrupt
markedli
reduc
infiltr
tumor
put
immunesuppress
tumor
promot
stromal
cell
studi
highlight
reduc
protumor
stromal
cell
effect
may
allevi
antivir
resist
yield
increas
overal
therapeut
efficaci
hand
paracrin
antivir
effect
tumorhom
monocyt
cell
could
select
abrog
cell
could
favor
use
ferri
oncolyt
virus
tumor
inde
signific
delay
metastat
tumor
potenti
achiev
macrophag
har
deliv
tumorspecif
oncolyt
adenoviru
antivir
statu
human
cancer
recent
analys
differ
normal
cell
occupi
organ
reveal
strike
function
variat
compon
type
ifn
signal
pathway
correl
tissu
tropism
virul
viru
strain
similar
variat
compon
found
cancer
cell
cancer
cell
make
except
transform
cell
undergo
select
elimin
immun
system
becom
cancer
term
immunoedit
base
observ
differenti
capac
immunocompet
mice
reject
tumor
previous
grown
immunocompromis
host
versu
syngen
anim
cancer
cell
respons
type
type
ii
ifn
play
role
immunoedit
cancer
cell
eventu
progress
form
tumor
display
reduc
capac
respond
ifn
gamma
otherwis
would
upregul
mhc
class
molecul
render
tumor
amen
cellmedi
destruct
wherea
respons
type
interferon
initi
help
tumor
avoid
immun
purg
edit
phase
irrelev
note
antitumor
effect
type
ifn
still
exploit
today
sever
cancer
shown
depend
host
nk
cell
mice
ifnar
block
monoclon
antibodi
fail
reject
even
highli
immunogen
tumor
oppos
mice
treat
control
antibodi
reject
immunogen
tumor
challeng
thu
wherea
tumor
respons
type
ifn
predetermin
immunoedit
factor
post
immunoedit
may
influenc
sever
tumor
type
vari
level
express
compon
type
ifn
signal
cascad
detect
tumor
type
compon
found
prognost
valu
wherea
other
seem
influenc
surviv
howev
emerg
data
suggest
antivir
gene
may
predict
poor
surviv
increas
treatment
resist
one
studi
poor
prognosi
sever
type
cancer
due
genotox
treatment
resist
found
correl
increas
activ
ifnipathway
gene
studi
triad
type
ifnsign
pathway
gene
form
pantumortyp
neg
prognost
factor
broader
sevengen
cluster
establish
neg
prognost
criteria
treatmentresist
breast
cancer
treatmentresist
subsequ
shown
depend
signal
tumor
clone
posit
select
anim
vivo
demonstr
increas
prolifer
metastat
potenti
mediat
resist
genotox
assault
doxorubicin
ioniz
radiat
knockdown
result
lower
prolifer
rate
metastat
capac
increas
sensit
genotox
stress
anoth
studi
resist
epigenet
dna
modifi
methyltransferas
inhibitor
histon
deacetylas
hdac
inhibitor
correl
increas
express
ifnipathway
gene
small
lung
cancer
cell
basal
ifnrel
gene
express
sever
differ
sml
cell
line
upregul
interestingli
mani
cancer
stat
protein
phosphoryl
persist
unphosphoryl
form
ustat
like
phosphoryl
counterpart
increas
express
gene
contribut
resist
dna
damag
agent
current
unknown
cancer
may
prefer
use
unphosphoryl
form
known
ustat
activ
distinct
signal
compar
phosphoryl
counterpart
howev
importantli
oncolyt
virus
mani
tumor
constant
express
releas
type
ifn
lead
constitut
high
level
unphosphoryl
form
togeth
form
unphosphoryl
function
complex
reloc
nucleu
drive
express
specif
set
isg
distinct
acut
ifn
exposur
isg
suffici
maintain
function
antivir
defens
play
critic
role
resist
dna
damag
agent
cellular
level
viru
replic
control
antivir
defens
molecul
turn
primarili
control
type
ifn
signal
addit
classic
type
ifn
cytokineinduc
antivir
signal
tumor
may
employ
antivir
defens
mechan
exampl
stromal
cell
may
secret
peptid
antivir
properti
call
defensin
defensin
amphiphat
typic
amino
acid
length
interfer
virus
physic
bind
disrupt
viru
particl
andor
induc
antivir
respons
target
cell
via
pattern
recognit
receptor
least
oral
squamou
cell
carcinoma
found
overexpress
defensin
compar
normal
control
tissu
role
defensin
oncolyt
viru
infect
tumor
unclear
one
studi
show
immunestimul
properti
defensin
may
exploit
increas
overal
therapeut
efficaci
studi
express
beta
defensin
condit
replic
adenoviru
yield
superior
therapeut
entiti
compar
unarm
parent
viru
via
enhanc
antitumor
immun
respons
mediat
activ
dendrit
cell
summari
human
cancer
display
vari
degre
express
antivir
protein
signal
regul
baselin
may
increas
respons
genotox
anticanc
treatment
next
chapter
highlight
consequ
oncolyt
virotherapi
heterogen
type
ifn
respons
tumor
cell
oncolyt
virus
test
date
display
variabl
infect
differ
cancer
cell
line
variabl
like
least
partli
depend
type
ifn
oncolyt
virus
ifnsensit
ifnsecret
follow
viru
sens
cell
via
tolllik
receptor
express
plasma
membran
endocytot
vesicl
nodlik
receptor
sting
nlp
inflammosom
danger
sens
molecul
summar
elsewher
virus
carri
arsen
counteract
molecul
viru
goe
complet
undetect
even
hsv
amplicon
devoid
function
viru
gene
induc
type
ifn
respons
mediat
systemwid
antivir
defens
mice
within
one
hour
intraven
vector
inject
result
signific
reduct
transgen
express
compar
express
knockout
anim
studi
attenu
sfv
vector
becam
appar
dramat
last
therapeut
efficaci
achiev
follow
mere
singl
intraven
intratumor
inject
viru
immunocompromis
mice
bear
human
melanoma
glioma
xenograft
go
recapitul
easili
immunocompet
anim
paradox
studi
oncolyt
sfv
vector
effect
replic
destroy
varieti
ifnrespons
cancer
cell
line
vitro
consist
fail
erad
tumor
gener
cell
type
vivo
even
larg
dose
viru
inject
directli
tumor
mass
even
tumor
void
visibl
physic
barrier
figur
convers
tumor
gener
ifnunrespons
cancer
cell
seem
infect
vivo
far
light
earlier
find
other
show
type
ifn
receptor
knockout
mice
highli
suscept
sfv
infect
quickli
succumb
multiorgan
system
infect
paramet
oncolyt
sfv
efficaci
seem
clear
tumor
cell
must
defect
type
ifn
respons
viru
effect
find
line
emerg
data
group
show
remark
strict
depend
oncolyt
viru
replic
defect
type
ifn
respons
dogma
introduc
turn
centuri
exampl
sarcoma
melanoma
display
differ
permiss
oncolyt
vsv
obstacl
may
overcom
block
type
ifn
signal
eight
sarcoma
cell
line
basal
upregul
rigi
rapid
induct
phosphoryl
upon
ifn
treatment
correl
resist
oncolyt
measl
viru
studi
human
pancreat
ovarian
cancer
cell
display
resist
rbdepend
oncolyt
adenoviru
strongli
correl
intracellular
level
mxa
acquir
resist
repeat
oncolyt
adenoviru
inject
intraperiton
ovarian
carcinoma
model
associ
increas
mxa
well
sever
key
isg
tumor
studi
compar
normal
human
mous
melanocyt
panel
melanoma
cell
reveal
strong
correl
permiss
oncolyt
vsv
capac
mount
antivir
defens
respons
type
ifn
studi
harbor
two
mutat
p
l
gene
superior
sever
test
oncolyt
vsv
strain
depend
defect
ifn
respons
still
retain
yet
anoth
studi
oncolyt
vsv
replic
four
twelv
mesothelioma
cell
line
unabl
mount
antivir
defens
upon
ifnbeta
pretreat
respond
infect
upregul
pkr
mxa
mrna
contrast
nonpermiss
mesothelioma
cell
mount
antivir
defens
associ
pkr
mxa
mrna
upregul
respons
infect
exogen
type
ifn
author
studi
link
observ
pattern
viru
resist
clinic
mesothelioma
sampl
mesothelioma
tissu
array
signific
varianc
immunoreact
pkr
andor
ifnar
observ
sampl
display
lack
reactiv
three
compon
argu
tumor
clinic
set
would
display
least
level
resist
oncolyt
vsv
oncolyt
adenovirus
often
delet
normal
bind
rb
prevent
sequest
result
virus
unabl
replic
normal
cell
howev
sinc
adenoviru
virus
contain
element
antagon
antivir
defens
element
also
target
delet
render
viru
sensit
innat
antivir
defens
would
expect
remain
intact
normal
cell
cancer
cell
express
ra
may
downregul
protein
kinas
r
inhibit
type
ifn
induct
interf
rigi
signal
also
select
interferon
stimul
gene
appear
repress
rasmekerk
signal
cascad
pkr
activ
shut
translat
includ
translat
viru
messeng
rna
therefor
adenoviru
delet
va
rna
antagon
pkr
capabl
replic
rasoverexpress
tumor
cell
howev
seemingli
case
later
discov
ra
obligatori
determin
pkrinactiv
viru
replic
halt
even
ra
overexpress
cell
via
function
pkrmediat
phosphoryl
impli
paramet
va
rnadelet
adenoviru
replic
revis
similar
find
obtain
oncolyt
reoviru
rasindepend
tumor
resist
emerg
vivo
thu
circumst
even
tumor
cell
overexpress
ra
may
respond
type
ifn
stimul
pattern
recognit
receptor
activ
pkr
inhibit
viru
translat
complic
matter
mekinhibitor
shown
restor
antivir
signal
capac
ra
overexpress
tumor
impli
human
tumor
treat
mekinhibitor
trametinib
recent
approv
treatment
brafmut
melanoma
may
poor
target
oncolyt
virus
antivir
signal
capac
tumor
may
restor
oncolyt
virus
member
poxviru
famili
seemingli
resist
antivir
effect
type
ifn
vitro
may
control
cellular
factor
howev
case
sensit
resist
type
ifn
assess
vitro
use
one
cytokin
may
mask
synergi
factor
present
vivo
one
possibl
explan
vivo
discrep
tumor
microenviron
impos
physic
barrier
oncolyt
virus
also
alter
intracellular
antivir
defens
exampl
glioma
cell
found
brain
spontan
secret
type
ifn
confer
resist
oncolyt
hsv
resist
link
ecm
protein
interact
glioma
cell
surfac
receptor
alpha
beta
integrin
activ
interferon
secret
tempt
specul
whether
similar
ecmgliomainteract
could
contribut
resist
syngen
glioma
cell
observ
vivo
vitro
oncolyt
sfv
vaccinia
viru
also
critic
mani
respect
antivir
signal
may
occur
without
signal
via
type
ifn
receptor
ifnar
instanc
upon
infect
ifnar
ko
mice
murin
hepat
viru
mhv
brain
cell
found
upregul
antivir
gtpase
tgtp
confirm
antivir
activ
vivo
varieti
virus
case
ifn
gamma
tnf
alpha
like
account
least
part
observ
isg
activ
eg
tgtp
upregul
signal
shown
induc
independ
ifnar
interestingli
cancer
heterogen
antivir
defenc
signal
one
broad
class
tumor
particular
may
display
consist
low
capac
ward
oncolyt
virus
oncovirusinduc
cancer
oncovirus
virus
carri
complement
factor
abrog
antivir
sensor
effector
may
result
tumor
uniformli
devoid
antivir
signal
intrigu
studi
oncolyt
vsv
infect
destroy
human
papilloma
viru
hpv
posit
cervic
carcinoma
cell
effect
hpvneg
head
neck
cancer
cell
due
hpv
suppress
antivir
signal
hpvposit
xenograft
effici
erad
nude
mice
follow
vsv
inject
potenti
approach
even
oncolyt
virus
extrem
sensit
type
ifn
attenu
sfv
mmutat
vsv
may
function
well
oncovirusinduc
cancer
oncoviru
machineri
ensur
lack
antivir
defens
first
thought
would
appear
counterintuit
antagon
factor
keep
oncolyt
virus
tumorspecif
emerg
data
show
accomplish
safe
way
one
foremost
strategi
increas
oncolyt
viru
efficaci
combin
drug
lower
tumor
antivir
defens
regard
primari
target
interfer
prototyp
type
ifn
signal
cascad
small
molecular
inhibitor
ifnar
avail
activ
downstream
signal
transduc
may
effect
block
human
pancreat
cancer
cell
shown
constitut
express
high
level
mxa
oa
mount
type
ifndepend
resist
oncolyt
vsv
resist
could
overcom
block
activ
ifnarassoci
janu
kinas
jak
similarli
inhibitor
ruxolitinib
overcam
type
ifndepend
resist
human
head
neck
cancer
cell
oncolyt
vsv
ruxolitinib
also
success
abrog
type
ifnmedi
antivir
effect
elicit
macrophag
highlight
drug
might
also
allevi
type
ifndepend
tumor
resist
oncolyt
virus
impos
stromal
cell
howev
obviou
downsid
use
effect
critic
host
defens
mechan
may
result
increas
infect
normal
cell
moreov
may
reduc
antitumor
immun
respons
elicit
oncolyt
virotherapi
exampl
ruxolitinib
shown
impair
capac
dendrit
cell
promot
cell
respons
model
tumor
antigen
hand
studi
clearanc
adenoviru
delay
ruxolitinibtr
normal
anim
make
difficult
predict
overal
impact
tumor
therapi
prolong
viru
presenc
might
translat
better
therapeut
efficaci
also
immunestimul
antitumor
effect
type
type
ii
interferon
may
advers
affect
jakinhibitor
central
tumorpromot
cascad
mediat
jak
may
also
inhibit
yield
difficulttopredict
net
therapeut
outcom
moment
studi
need
establish
overal
impact
interfer
signal
cancer
therapi
spur
earlier
report
oncoviru
reactiv
promot
enhanc
histon
deacetylas
hdac
inhibitor
class
agent
assess
capac
enhanc
oncolyt
viru
potenc
inhibit
antivir
respons
inde
enhanc
observ
oncolyt
vsv
sfv
difficult
pinpoint
exact
mechan
underli
hdacinhibitor
enhanc
oncolyt
viru
replic
cancer
cell
antivir
defens
gener
yet
unknown
reason
mainli
cancer
cell
normal
cell
indirectli
facilit
viru
replic
interestingli
combin
hdac
inhibitor
condit
replic
adenoviru
gave
improv
viru
replic
rate
therapeut
efficaci
subcutan
xenograft
model
inhibitor
given
viru
otherwis
inhibit
replic
observ
similarli
hdac
inhibitor
increas
replic
oncolyt
efficaci
hsv
given
viru
given
time
nuclear
dna
virus
adenoviru
hsv
possibl
hdac
inhibitor
also
alter
viru
genom
access
transcript
factor
result
reduc
replic
advers
effect
impli
virus
hdac
inhibitor
administ
virus
recent
found
hdac
inhibitor
vorinostat
activ
signal
facilit
hyperacetyl
subunit
turn
activ
cellular
autophagi
autophagi
anoth
studi
shown
import
vsv
replic
presum
inhibit
antivir
signal
interest
previou
studi
reveal
enhanc
vsv
replic
inhibit
tnfalphainduc
antivir
signal
mediat
use
inhibitor
studi
neither
inhibitor
effect
phosphoryl
nuclear
reloc
respons
type
ifn
author
observ
clear
induct
respons
type
ifn
glioma
cell
latter
two
depend
signal
taken
togeth
pathway
activ
may
result
differ
antivir
respons
differ
cancer
type
inhibit
enhanc
oncolyt
virus
inhibitor
depend
concomit
cellular
mechan
autophagi
sinc
hdac
inhibitor
modul
promot
activityaccess
conceiv
epigenet
promot
modifi
agent
could
work
similar
manner
repress
antivir
defens
induct
enhanc
oncolyt
virus
dna
demethyl
agent
decitabin
synerg
oncolyt
herp
simplex
type
viru
glioma
model
vitro
vivo
hdac
inhibitor
valproic
acid
vpa
alreadi
shown
work
well
oncolyt
hsv
well
sever
oncolyt
virus
moreov
inhibit
cancer
antivir
defens
specif
rnasel
pkr
result
cancer
cell
expos
sunitinib
multityrosin
kinas
inhibitor
origin
develop
inhibitor
vegfr
pdgfr
signal
yield
strong
antitumor
synergi
ifnsensit
oncolyt
vsv
sinc
sunitinib
approv
renal
cell
carcinoma
imatinibresist
gastric
cancer
combin
oncolyt
vsv
constitut
promis
clinic
relev
approach
warrant
investig
interstingli
sunitinib
well
sever
receptor
tyrosin
kinas
inhibitor
display
antivir
effect
polyomaviru
bk
argu
compound
univers
viru
enhanc
cyclophosphamid
cpa
gener
immunosuppress
use
minim
treg
presenc
immunotherapi
also
oncolyt
virotherapi
cpa
may
howev
also
enhanc
replic
efficaci
oncolyt
virus
diminish
cytokin
secret
stromal
cell
includ
type
ifn
anoth
compound
enhanc
oncolyt
viru
efficaci
lower
cell
respons
type
ifn
triptolid
act
downstream
activ
kinas
mammalian
target
rapamycin
mtor
enhanc
antivir
effect
type
ifn
activ
effector
protein
bind
inactiv
translat
factor
carri
celltyp
specif
signal
function
type
ifn
activ
eukaryot
translat
initi
factor
promot
transcript
consequ
rapamycin
abl
enhanc
oncolyt
vsv
replic
antitumor
efficaci
inhibit
type
ifnmedi
antivir
signal
via
mtor
sever
compound
synerg
oncolyt
virus
identifi
via
highthroughput
drug
librari
screen
mani
seem
act
antagon
antivir
defens
instanc
novel
viru
sensit
found
greatli
diminish
antivir
effect
type
ifn
oncolyt
vsv
sever
cancer
cell
type
drug
also
synerg
viru
subcutan
mous
tumor
model
mani
new
compound
mechan
action
still
poorli
understood
necessit
extens
safeti
studi
exclud
undesir
effect
normal
cell
apart
classic
type
ifninduc
antivir
defens
typic
prevent
viru
translat
degrad
viru
genom
cellular
machineri
regul
oncolyt
viru
efficaci
notabl
strategi
increas
cancer
cell
death
respons
oncolyt
virus
test
recent
studi
class
compound
call
smac
mimet
synerg
sever
cancer
model
oncolyt
vsv
remov
cancer
cell
block
apoptosi
respons
virusinduc
type
ifn
trail
interestingli
sinc
viru
infectiontrigg
cytokin
act
nearbi
noninfect
cell
smac
mimet
may
combin
oncolyt
virus
also
caus
signific
bystand
tumordestruct
normal
cell
affect
ifnsmac
mimet
synergi
provid
import
safeti
aspect
anoth
studi
block
er
stress
respons
circuitri
trigger
oncolyt
rhabdoviru
infect
small
molecular
inhibitor
serinethreonin
protein
kinas
endoribonucleas
identifi
genomewid
sirna
screen
greatli
enhanc
cytotox
via
apoptosi
increas
oncolyt
efficaci
refractori
tumor
model
mice
effect
independ
induct
respons
type
ifn
convers
inhibitor
nucleosid
discov
highthroughput
screen
enhanc
oncolyt
hsv
date
inhibitor
report
alter
cellular
antivir
respons
compound
common
chemotherapeut
mechan
synerg
oncolyt
virus
discuss
possibl
role
antivir
defens
antagon
enhanc
oncolyt
viru
efficaci
remain
studi
thu
mani
compound
avail
interfer
tumor
antivir
defens
outstand
question
howev
seem
compound
render
normal
cell
sensit
oncolyt
virus
elucid
exact
mechan
action
differ
normal
cancer
cell
constitut
worthi
goal
studi
near
futur
alreadi
becam
clear
use
certain
pathogen
wildtyp
virus
west
nile
viru
bunyamwera
viru
cancer
patient
would
result
offtarget
toxic
characterist
pathogen
virus
greater
abil
circumv
antagon
cellular
innat
antivir
defens
attenu
strain
exampl
unlik
prototyp
oncolyt
reoviru
strain
type
dear
strain
reoviru
caus
accumul
nucleu
inhibit
activ
select
group
properti
strain
myocardit
unlik
oncolyt
type
dear
strain
reason
mani
oncolyt
virus
use
today
reoviru
type
dear
oncolyt
strain
newcastl
diseas
viru
mmutat
vsv
either
stronger
capac
induc
weaker
capac
resist
antivir
type
ifn
correspond
wildtyp
strain
open
question
howev
whether
strainspecif
virusspecif
differ
relat
specif
compon
cellular
antivir
machineri
may
exploit
greater
antitumor
efficaci
ie
one
viru
fail
could
anoth
use
stead
ra
express
critic
oncolyt
reoviru
replic
cell
overexpress
oncogen
oncolyt
vesicular
stomat
viru
unabl
replic
cell
due
increas
activ
thu
cell
reoviru
affect
therefor
remain
interest
see
antivir
effector
may
lack
cell
convers
reoviru
vsv
differ
term
sensit
antivir
effector
sever
oncolyt
virus
compar
term
replic
rate
cytotox
systemat
studi
regard
tumor
antivir
defens
conduct
attenu
viru
like
replic
effect
nich
ie
restrict
specif
set
isg
wild
type
strain
may
toxic
use
human
compromis
may
achiev
incorpor
select
element
wild
type
virus
oncolyt
viru
backbon
inde
sever
chimer
recombin
virus
gener
harbor
specif
element
wild
type
strain
even
unrel
virus
order
better
resist
cancer
antivir
defens
tabl
exampl
introduc
wild
type
element
attenu
virus
haralambieva
report
measl
viru
edmonston
vaccin
strain
p
gene
replac
counterpart
wild
type
icb
strain
later
meng
et
al
includ
n
p
l
gene
wild
type
measl
edmonston
backbon
produc
enhanc
still
safe
oncolyt
viru
edmonston
vaccin
viru
induc
robust
ifnrespons
compar
wild
type
measl
viru
partli
due
weaker
abil
v
protein
suppress
activ
ifni
induct
vivo
pgene
encod
protein
particularli
v
control
qualiti
cytokin
respons
measl
vaccin
strain
qualit
induc
stronger
inflammatori
respons
compar
wt
strain
wt
v
protein
suppress
multipl
cytokin
secret
v
protein
short
cytoplasm
tail
shown
bind
inactiv
rel
homolog
domain
subunit
also
v
caus
protein
bind
inactiv
rigi
seemingli
interfer
trif
multipl
tlr
adaptor
includ
mediat
induct
thu
cancer
normal
cell
would
differ
regard
viru
could
potenti
target
specif
cancer
cell
rather
normal
cell
far
measl
edmonstonwt
chimera
proven
safe
anim
exampl
heterolog
viru
construct
lentogen
newcastl
diseas
viru
engin
express
influenza
viru
show
enhanc
oncolyt
efficaci
vivo
due
dampen
antivir
respons
viru
display
enhanc
pathogen
studi
mesogen
ndv
viru
harbor
influenza
strain
show
increas
pathogen
chicken
well
increas
abil
replic
human
cell
rais
cautionari
warn
futur
engin
similar
replic
virus
anoth
exampl
vaccinia
viru
solubl
type
ifn
scaveng
note
often
use
literatur
engin
oncolyt
hsv
oncolyt
rhabdovirus
result
case
effect
therapi
agent
without
loss
tumor
specif
oncolyt
gene
delet
hsv
complement
two
differ
pkrantagonist
human
cytomegaloviru
gener
chimera
capabl
reach
wild
type
viru
replic
level
cancer
cell
vitro
tumor
model
vivo
select
variou
viral
ifniantagonist
potenti
could
use
augment
attenu
oncolyt
virus
vast
exampl
increas
replic
sever
virus
includ
sindbi
viru
adenoviru
mammalian
cell
observ
cell
engin
express
vaccinia
viru
protein
influenza
viru
protein
ebola
viru
protein
tat
protein
choic
antagonist
must
primarili
made
safeti
mind
virusspecif
cellspecif
differ
antagonist
function
may
potenti
exploit
ration
consid
overal
combin
exampl
vaccinia
viru
abl
rescu
vsv
emcv
exogen
ifn
wherea
vaccinia
viru
partial
rescu
emcv
vsv
anticip
systemat
perhap
bioinformat
guid
superchimera
studi
two
virus
may
complement
shortcom
antivir
defens
antagon
consid
notabl
vaccinia
viru
favor
combin
ifnisensit
oncolyt
vsv
sfv
yield
tumormodeldepend
increas
overal
therapi
efficaci
depend
vaccinia
viru
antagon
type
ifn
respons
increas
replic
ifnsensit
virus
heterolog
virotherapi
approach
may
also
use
gener
immunolog
synergi
similar
heterolog
primeboost
vaccin
antitumor
immun
respons
may
increas
due
target
tumor
two
differ
virus
two
separ
occas
antiviru
immun
respons
would
gener
differ
virus
time
avoid
problem
neutral
immun
predomin
antiviru
immun
respons
idea
explor
experiment
includ
engin
oncolyt
virus
express
oncolyt
virus
exampl
entir
oncolyt
parvoviru
genom
place
regulat
promot
oncolyt
adenoviru
result
effect
therapeut
entiti
either
viru
alon
without
loss
tumorspecif
genet
materi
semliki
forest
viru
replicon
engin
adenoviru
vaccinia
viru
backbon
sever
viru
chimera
construct
howev
effect
tumor
antivir
defens
construct
remain
studi
attribut
oncolyt
impli
viru
infect
inde
lyse
infect
tumor
properti
primarili
test
vitro
cultur
tumor
cell
learn
howev
nativ
tumor
microenviron
live
host
mani
virus
longer
abl
infect
tumor
cell
kill
even
manag
infect
tightli
pack
tumor
cell
network
support
molecul
extracellular
matrix
form
physic
barrier
viru
particl
diffus
also
becom
evid
tumor
cell
may
much
capabl
thwart
oncolyt
viru
advanc
previous
thought
tumor
cell
resid
seemingli
perman
nonpermiss
antivir
state
tumor
harbor
multipl
cell
type
addit
neoplast
cell
may
promot
propag
physic
cellular
viru
resist
efficaci
virotherapi
human
cancer
patient
still
fall
shi
achiev
anim
model
appear
quit
plausibl
one
barrier
describ
review
inde
constitut
real
formid
obstacl
oncolyt
viru
advanc
routin
clinic
use
fortun
difficult
barrier
identifi
rapidli
expand
arsen
countermeasur
dispos
task
separ
wheat
chaff
systemat
evalu
propos
combin
regimen
yield
best
result
without
compromis
patient
safeti
